Corbevax effective on kids in phase II, III trials

The phase II and III clinical trials of Corbevax for children between five and 18 years have shown the vaccine is safe and fights the Covid-19 infection. The vaccine successfully nullified the effect of both the ancestral strain of Covid-19 from Wuhan and its progeny Delta strain.

from Hyderabad News: Latest Hyderabad News Headlines & Live News Updates from Hyderabad - Times of India https://ift.tt/OLGwhpy